Germline mutations in FH confer predisposition to malignant pheochromocytomas and paragangliomas
Top Cited Papers
Open Access
- 13 December 2013
- journal article
- research article
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 23 (9) , 2440-2446
Abstract
Malignant pheochromocytoma (PCC) and paraganglioma (PGL) are mostly caused by germline mutations of SDHB, encoding a subunit of succinate dehydrogenase. Using whole-exome sequencing, we recently identified a mutation in the FH gene encoding fumarate hydratase, in a PCC with an ‘SDH-like’ molecular phenotype. Here, we investigated the role of FH in PCC/PGL predisposition, by screening for germline FH mutations in a large international cohort of patients. We screened 598 patients with PCC/PGL without mutations in known PCC/PGL susceptibility genes. We searched for FH germline mutations and large deletions, by direct sequencing and multiplex ligation-dependent probe amplification methods. Global alterations in DNA methylation and protein succination were assessed by immunohistochemical staining for 5-hydroxymethylcytosine (5-hmC) and S-(2-succinyl) cysteine (2SC), respectively. We identified five pathogenic germline FH mutations (four missense and one splice mutation) in five patients. Somatic inactivation of the second allele, resulting in a loss of fumarate hydratase activity, was demonstrated in tumors with FH mutations. Low tumor levels of 5-hmC, resembling those in SDHB-deficient tumors, and positive 2SC staining were detected in tumors with FH mutations. Clinically, metastatic phenotype (P = 0.007) and multiple tumors (P = 0.02) were significantly more frequent in patients with FH mutations than those without such mutations. This study reveals a new role for FH in susceptibility to malignant and/or multiple PCC/PGL. Remarkably, FH-deficient PCC/PGLs display the same pattern of epigenetic deregulation as SDHB-mutated malignant PCC/PGL. Therefore, we propose that mutation screening for FH should be included in PCC/PGL genetic testing, at least for tumors with malignant behavior.Keywords
This publication has 27 references indexed in Scilit:
- Oncometabolites: linking altered metabolism with cancerJournal of Clinical Investigation, 2013
- SDH Mutations Establish a Hypermethylator Phenotype in ParagangliomaCancer Cell, 2013
- Inhibition of α-KG-dependent histone and DNA demethylases by fumarate and succinate that are accumulated in mutations of FH and SDH tumor suppressorsGenes & Development, 2012
- Epithelial to Mesenchymal Transition Is Activated in Metastatic Pheochromocytomas and Paragangliomas Caused by SDHB Gene MutationsThe Journal of Clinical Endocrinology & Metabolism, 2012
- An Update on the Genetics of Paraganglioma, Pheochromocytoma, and Associated Hereditary SyndromesHormone and Metabolic Research, 2012
- Pheochromocytomas: The (pseudo)-hypoxia hypothesisBest Practice & Research Clinical Endocrinology & Metabolism, 2010
- Succinate Dehydrogenase B Gene Mutations Predict Survival in Patients with Malignant Pheochromocytomas or ParagangliomasThe Journal of Clinical Endocrinology & Metabolism, 2007
- Mitochondrial succinate is instrumental for HIF1α nuclear translocation in SDHA-mutant fibroblasts under normoxic conditionsHuman Molecular Genetics, 2005
- Year of Diagnosis, Features at Presentation, and Risk of Recurrence in Patients with Pheochromocytoma or Secreting ParagangliomaThe Journal of Clinical Endocrinology & Metabolism, 2005
- Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-α prolyl hydroxylaseCancer Cell, 2005